Ten months after an FDA complete response letter (CRL) set back efforts by Teva Pharmaceutical Industries Ltd. to gain its first approval for Austedo (deutetrabenazine), an agency review has finally led to approval for the orphan-designated drug, a treatment for chorea – involuntary, random and sudden, twisting and/or writhing movements – associated with Huntington's disease (HD).